281 related articles for article (PubMed ID: 36308562)
21. Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom.
Chakraborty S; Uprety R; Daibani AE; Rouzic VL; Hunkele A; Appourchaux K; Eans SO; Nuthikattu N; Jilakara R; Thammavong L; Pasternak GW; Pan YX; McLaughlin JP; Che T; Majumdar S
ACS Chem Neurosci; 2021 Jul; 12(14):2661-2678. PubMed ID: 34213886
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): A systematic review.
Ya K; Tangamornsuksan W; Scholfield CN; Methaneethorn J; Lohitnavy M
Asian J Psychiatr; 2019 Jun; 43():73-82. PubMed ID: 31100603
[TBL] [Abstract][Full Text] [Related]
23. The neuromuscular blockade produced by pure alkaloid, mitragynine and methanol extract of kratom leaves (Mitragyna speciosa Korth.).
Chittrakarn S; Keawpradub N; Sawangjaroen K; Kansenalak S; Janchawee B
J Ethnopharmacol; 2010 Jun; 129(3):344-9. PubMed ID: 20371282
[TBL] [Abstract][Full Text] [Related]
24. Update on the Pharmacology and Legal Status of Kratom.
Prozialeck WC
J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
[TBL] [Abstract][Full Text] [Related]
25. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy.
Harun N; Kamaruzaman NA; Mohamed Sofian Z; Hassan Z
Neurosci Lett; 2022 Mar; 773():136500. PubMed ID: 35114335
[TBL] [Abstract][Full Text] [Related]
26. The effects of chronic mitragynine (Kratom) exposure on the EEG in rats.
Suhaimi FW; Hassan Z; Mansor SM; Müller CP
Neurosci Lett; 2021 Feb; 745():135632. PubMed ID: 33444671
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo pharmacology of kratom.
Hiranita T; Obeng S; Sharma A; Wilkerson JL; McCurdy CR; McMahon LR
Adv Pharmacol; 2022; 93():35-76. PubMed ID: 35341571
[TBL] [Abstract][Full Text] [Related]
28. Plant growth and phytoactive alkaloid synthesis in kratom [Mitragyna speciosa (Korth.)] in response to varying radiance.
Zhang M; Sharma A; León F; Avery B; Kjelgren R; McCurdy CR; Pearson BJ
PLoS One; 2022; 17(4):e0259326. PubMed ID: 35472200
[TBL] [Abstract][Full Text] [Related]
29. Self-reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects.
Saref A; Suraya S; Singh D; Grundmann O; Narayanan S; Swogger MT; Prozialeck WC; Boyer E; Chear NJY; Balasingam V
J Ethnopharmacol; 2019 Jun; 238():111876. PubMed ID: 31014959
[TBL] [Abstract][Full Text] [Related]
30. Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects.
Grundmann O; Hill K; Al Barzanji E; Hazrat NG; Kaur G; Negeve RE; Shade S; Weber S; Veltri CA
J Ethnopharmacol; 2023 Dec; 317():116779. PubMed ID: 37364801
[TBL] [Abstract][Full Text] [Related]
31. Kratom (Mitragyna speciosa): worldwide issues.
Ramanathan S; McCurdy CR
Curr Opin Psychiatry; 2020 Jul; 33(4):312-318. PubMed ID: 32452943
[TBL] [Abstract][Full Text] [Related]
32. Opioid receptors mediate the acquisition, but not the expression of mitragynine-induced conditioned place preference in rats.
Yusoff NHM; Mansor SM; Müller CP; Hassan Z
Behav Brain Res; 2017 Aug; 332():1-6. PubMed ID: 28559179
[TBL] [Abstract][Full Text] [Related]
33. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.
Hemby SE; McIntosh S; Leon F; Cutler SJ; McCurdy CR
Addict Biol; 2019 Sep; 24(5):874-885. PubMed ID: 29949228
[TBL] [Abstract][Full Text] [Related]
34. A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products.
Fowble KL; Musah RA
Forensic Sci Int; 2019 Jun; 299():195-202. PubMed ID: 31059866
[TBL] [Abstract][Full Text] [Related]
35. A case of fatal overdose involving both hydromorphone and kratom.
Shi T; Shea JL
J Forensic Sci; 2024 Jan; 69(1):355-358. PubMed ID: 37753815
[TBL] [Abstract][Full Text] [Related]
36. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa.
Matsumoto K; Horie S; Ishikawa H; Takayama H; Aimi N; Ponglux D; Watanabe K
Life Sci; 2004 Mar; 74(17):2143-55. PubMed ID: 14969718
[TBL] [Abstract][Full Text] [Related]
37. Development of a Physiologically Based Pharmacokinetic Model of Mitragynine, Psychoactive Alkaloid in Kratom (
Ya K; Methaneethorn J; Tran QB; Trakulsrichai S; Wananukul W; Lohitnavy M
J Psychoactive Drugs; 2021; 53(2):127-139. PubMed ID: 34003732
[TBL] [Abstract][Full Text] [Related]
38. Mitragynine (Kratom)-Withdrawal behaviour and cognitive impairments can be ameliorated by an epigenetic mechanism.
Yunusa S; Müller CP; Hassan Z
Br J Pharmacol; 2024 Jul; 181(13):2070-2084. PubMed ID: 38523471
[TBL] [Abstract][Full Text] [Related]
39. Lateral Flow Assessment and Unanticipated Toxicity of Kratom.
Smith LC; Lin L; Hwang CS; Zhou B; Kubitz DM; Wang H; Janda KD
Chem Res Toxicol; 2019 Jan; 32(1):113-121. PubMed ID: 30380840
[TBL] [Abstract][Full Text] [Related]
40. An in vitro evaluation of kratom (Mitragyna speciosa) on the catalytic activity of carboxylesterase 1 (CES1).
Melchert PW; Zhang Q; Mukhopadhyay S; Kanumuri SRR; McCurdy CR; Markowitz JS
Chem Biol Interact; 2023 Oct; 384():110715. PubMed ID: 37716419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
